However, the assessment of tTMB and PD-L1 expression from tissue biopsy samples became challenging in patients with advanced NSCLC, due to inadequate sample quality and quantity, risk of bleeding, spatial and temporal heterogeneity of tumor lesions, and dynamic host immunity. Here, CD274 is linked to non-small cell lung carcinoma.